ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.

Boyer, Michael; A. Jänne, Pasi; Mok, Tony; J. O’Byrne, Kenneth; Paz‐Ares, Luis; S. Ramalingam, Suresh; Liang, Jane; W. Taylor, Ian; Campbell, Alicyn; O’Connell, Joseph; P. Letrent, Stephen; Antic, Vladan

doi:10.1200/jco.2012.30.15_suppl.tps7615

Public

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.

Published in Journal of Clinical Oncology • May 20, 2012

Authors:

Michael Boyer

Pasi A. Jänne

Tony Mok

Abstract

TPS7615 Background: D is a highly selective irreversible small molecule inhibitor of all catalytically active members of the HER (human epidermal growth factor receptor) family of tyrosine kinases. In a randomized phase II trial in patients (pts) who had received 1–2 prior systemic therapy regimens ...

View

Paywalled

Subject

Medicine

Internal medicine

Erlotinib

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions